Company
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 34 of 55
A breakthrough therapy designation is designed to expedite the development and review of medicines that are intended to treat a serious condition and have shown promise in early-stage clinical trials
Two of its COPD drugs, Tudorza and Duaklir, have been given the thumbs-up from US regulators
The £2.7bn share placing will be used to make an upfront payment to Daiichi Sankyo, which has developed a potentially breakthrough new treatment for breast cancer
Investments and investor services
Footsie closed at 7,279, up nearly 45 points on the day
“We look forward to bringing Forxiga to a patient population that has not had any approved oral medicines available before," said Elisabeth Björk, AZ’s head of cardiovascular, renal and metabolism
Investments and investor services
Bercow says the government can only bring back the vote if there has been substantial 'change' to the Brexit deal
The UK's premier share index closed down around 32 points at 7,074
Archive
Its set to be a busy day for blue-chip news in London on Thursday.
Lynparza though showed significantly increased rates of survival in the phase III POLO trial
The company said during the trial Brilinta, when taken in conjunction with aspirin, had shown “a statistically-significant reduction” in major adverse cardiovascular events, such as heart attacks or strokes, compared to taking aspirin alone
Archive
The Week Ahead will also bring a trading update from AB Foods, plus final results from Standard Chartered, IAG, Persimmon, Rightmove, as well as the latest US GDP data
Patent expiries on key blockbusters such as Crestor and Seroquel have put a huge dent in sales over the past decade or so, but Astra returned to growth in 2018
Archive
FTSE 100 closed up just over six points at 7,197, while FTSE 250 shed over 74 at 18,898
Archive
AstraZeneca, Indivior and Coca-Cola HBC are among the higher profile names in the schedule for Thursday.
Archive
The UK's premier share index added almost 58 points at 7,129, while the FTSE 250 also gained ground
Archive
Aside from all the company news, the Week Ahead also brings the latest UK inflation and GDP growth data for investors to digest, while the Brexit saga will continue to roll on
MEDI8897 is being developed as a treatment for a respiratory syncytial virus – a major cause of lower respiratory tract infection which affects around 90% of children under two
JPMorgan's European Best Equity Ideas list summarises the bank’s EMEA Equity research team’s views and top picks, covering both strategy and sector contributions
Baselga resigned from his position as physician-in-chief at Memorial Sloan Kettering Cancer Center last year amid reports that he had failed to disclose payments from healthcare companies in some of his research articles
On the agenda at this year's Biotech Showcase is a panel discussion entitled “Cell and gene therapy: The financing surge” featuring Orgenesis CEO Vered Caplan
